Granted Patent
B2
US 12,433,837 · App. 18/177,875 · Granted Oct 7, 2025
Systems and methods for delivery of a therapeutic agent
Assignee:
The Foundry, LLC
A61K9/0021A61B18/1492A61B18/1815A61K9/0078A61K38/164A61K38/168A61K38/4893A61K41/00A61K41/0028A61K41/0047A61M37/00A61M37/0092A61N1/08A61N1/303A61N1/327A61N5/10A61N7/00C12Y304/24069A61B2018/0016A61B2018/00214A61B2018/00434A61B2018/1861A61M2210/1035A61N2007/003Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
Claims (34)
1. Apparatus for treating tissue in a nasal cavity, the apparatus comprising:
an elongate body, comprising:
a proximal portion; and
a distal portion configured for positioning in a nasal cavity;
a first electrode comprising a first pair of electrodes and a second electrode comprising a second pair of electrodes, the first electrode and second electrode being spaced away from one another and coupled with the distal portion of the elengate body and configured to deliver energy to a target tissue in the nasal cavity; and
a generator coupled with the proximal portion of the elongate body for supplying energy to at least one of the first electrode or the second electrode to treat the target tissue in the nasal cavity, the generator configured to deliver the energy in pulses between 1 V and 500 V.
2. The apparatus of claim 1 , wherein the first pair of electrodes and the second pair of electrodes each comprise bipolar radiofrequency electrodes.
3. The apparatus of claim 1 , wherein the generator comprises a radiofrequency generator.
4. The apparatus of claim 1 , wherein each of the first pair of electrodes and the second pair of electrodes comprise bipolar radiofrequency electrodes that are movable relative to the distal portion of the elongate body.
5. The apparatus of claim 4 , wherein each of the first pair of electrodes and the second pair of electrodes comprise bipolar radiofrequency electrodes that are configured to deliver energy laterally relative to the distal portion of the elongate body.
6. The apparatus of claim 4 , wherein each of the first pair of electrodes and the second pair of electrodes comprise bipolar radiofrequency electrodes that are configured to penetrate nasal mucosa lining the nasal cavity.
7. The apparatus of claim 1 , wherein each of the first pair of electrodes and the second pair of electrodes comprises a treatment electrode and a stimulating electrode.
8. The apparatus of claim 7 , further comprising a monitoring system operatively coupled to the first electrode and the second electrode for measuring a degree of treatment of the target tissue.
9. Apparatus for treating tissue in a nasal cavity, the apparatus comprising:
an elongate body, comprising:
a proximal portion; and
a distal portion configured for positioning in a nasal cavity;
a first electrode comprising a first pair of electrodes and a second electrode comprising a second pair of electrodes, the first electrode and second electrode being spaced away from one another and coupled with the distal portion of the elongate body and configured to deliver energy to a target tissue in the nasal cavity; and
a generator coupled with the proximal portion of the elongate body for supplying energy to at least one of the first electrode or the second electrode to treat the target tissue in the nasal cavity, the generator configured to deliver the energy in pulses between 1 V and 500 V,
wherein the first electrode and the second electrode are configured to be activated with energy from the generator in a sequential manner.
10. The apparatus of claim 9 , wherein the generator comprises a radiofrequency generator.
11. The apparatus of claim 9 , wherein the first pair of electrodes and the second pair of electrodes each comprise bipolar radiofrequency electrodes.
12. Apparatus for treating tissue in a nasal cavity, the apparatus comprising:
an elongate body, comprising:
a proximal portion, and
a distal portion configured for positioning in a nasal cavity,
a first pair of electrodes and a second pair of electrodes being spaced away from one another at the distal portion of the elongate body and configured to deliver energy to a target tissue in the nasal cavity, and
a generator coupled with the proximal portion of the elongate body for supplying radiofrequency energy to at least one of the first pair of electrodes or the second pair of electrodes to treat the target tissue in the nasal cavity, the generator configured to deliver the radiofrequency energy in pulses between 1 V and 500 V and for a duration between 5 microseconds to 100 milliseconds.
13. The apparatus of claim 1, 9, or 12 , wherein at least the first pair of electrodes comprise bipolar radiofrequency electrodes, wherein the bipolar radiofrequency electrodes are configured to deliver non-reversible poration energy to the target tissue in the nasal cavity.
14. The apparatus of claim 13 , wherein the bipolar radiofrequency electrodes comprise non-penetrating surface electrodes.
15. The apparatus of claim 14 , wherein the bipolar radiofrequency electrodes are configured to deliver the non-reversible poration energy laterally relative to the distal portion of the elongate body.
16. The apparatus of claim 15 , wherein the target tissue in the nasal cavity comprises goblet cells.
17. The apparatus of claim 16 , wherein an outer surface of the bipolar radiofrequency electrodes is planar with an outer surface of the elongate body.
18. The apparatus of claim 17 , wherein the elongate body defines a portion of a flexible catheter, wherein the flexible catheter comprises a sheath for housing the elongate body, wherein the distal portion of the elongate body is steerable.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 3, 2023
From: DEEM, MARK E.; GIFFORD, HANSON
To: THE FOUNDRY INC.
Reel/Frame 062870/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 3, 2023
From: THE FOUNDRY, INC.
To: THE FOUNDRY, LLC
Reel/Frame 062870/0650 →
Continuity (12)
Provisional Application
60702077
· Jul 22, 2005
References Cited (394)
US 874178A
· DeForest
· 1907
[cited by applicant]
US 1695107A
· Kahl
· 1928
[cited by applicant]
US 2566806A
· Miller
· 1951
[cited by applicant]
US 3117571A
· Fry et al.
· 1964
[cited by applicant]
US 3463149A
· Albu et al.
· 1969
[cited by applicant]
US 3469139A
· Colvin et al.
· 1969
[cited by applicant]
US 3538919A
· Meyer
· 1970
[cited by applicant]
US 3788296A
· Klatt et al.
· 1974
[cited by applicant]
US 3918449A
· Pistor
· 1975
[cited by applicant]
US 3941121A
· Olinger et al.
· 1976
[cited by applicant]
US 4271848A
· Turner et al.
· 1981
[cited by applicant]
US 4411266A
· Cosman
· 1983
[cited by applicant]
US 4658836A
· Turner
· 1987
[cited by applicant]
US 4767402A
· Kost et al.
· 1988
[cited by applicant]
US 4976710A
· Mackin
· 1990
[cited by applicant]
US 5056529A
· De Groot
· 1991
[cited by applicant]
US 5139029A
· Fishman et al.
· 1992
[cited by applicant]
US 5158536A
· Sekins et al.
· 1992
[cited by applicant]
US 5192290A
· Hilal
· 1993
[cited by applicant]
US 5255679A
· Imran
· 1993
[cited by applicant]
US 5286254A
· Shapland et al.
· 1994
[cited by applicant]
US 5304120A
· Crandell et al.
· 1994
[cited by applicant]
US 5331947A
· Shturman
· 1994
[cited by applicant]
US 5336178A
· Kaplan et al.
· 1994
[cited by applicant]
US 5409483A
· Campbell et al.
· 1995
[cited by applicant]
US 5432092A
· Bailey et al.
· 1995
[cited by applicant]
US 5496304A
· Chasan
· 1996
[cited by applicant]
US 5505730A
· Edwards
· 1996
[cited by applicant]
US 5507725A
· Savage et al.
· 1996
[cited by applicant]
US 5562608A
· Sekins et al.
· 1996
[cited by applicant]
US 5562720A
· Stern et al.
· 1996
[cited by applicant]
US 5575788A
· Baker et al.
· 1996
[cited by applicant]
US 5766605A
· Sanders et al.
· 1998
[cited by applicant]
US 5807306A
· Shapland et al.
· 1998
[cited by applicant]
US 5817073A
· Krespi
· 1998
[cited by applicant]
US 5820589A
· Torgerson et al.
· 1998
[cited by applicant]
US 5843088A
· Barra et al.
· 1998
[cited by applicant]
US 5860974A
· Abele
· 1999
[cited by applicant]
US 5891134A
· Goble et al.
· 1999
[cited by applicant]
US 5902268A
· Saab
· 1999
[cited by applicant]
US 5957961A
· Maguire et al.
· 1999
[cited by applicant]
US 5964223A
· Baran
· 1999
[cited by applicant]
US 5972026A
· Laufer et al.
· 1999
[cited by applicant]
US 6033397A
· Laufer et al.
· 2000
[cited by applicant]
US 6056744A
· Edwards
· 2000
[cited by applicant]
US 6063768A
· First
· 2000
[cited by applicant]
US 6109268A
· Thapliyal et al.
· 2000
[cited by applicant]
US 6139845A
· Donovan
· 2000
[cited by applicant]
US 6200333B1
· Laufer
· 2001
[cited by applicant]
US 6216704B1
· Ingle et al.
· 2001
[cited by applicant]
US 6265379B1
· Donovan
· 2001
[cited by applicant]
US 6273886B1
· Edwards et al.
· 2001
[cited by applicant]
US 6283989B1
· Laufer et al.
· 2001
[cited by applicant]
US 6299633B1
· Laufer
· 2001
[cited by applicant]
US 6302780B1
· Ahn et al.
· 2001
[cited by applicant]
US 6306423B1
· Donovan et al.
· 2001
[cited by applicant]
US 6322559B1
· Daul Ton et al.
· 2001
[cited by applicant]
US 6358926B2
· Donovan
· 2002
[cited by applicant]
US 6361554B1
· Brisken
· 2002
[cited by applicant]
US 6383509B1
· Donovan et al.
· 2002
[cited by applicant]
US 6411852B1
· Danek et al.
· 2002
[cited by applicant]
US 6425887B1
· McGuckin et al.
· 2002
[cited by applicant]
US 6432092B2
· Miller
· 2002
[cited by applicant]
US 6447785B1
· Donovan
· 2002
[cited by applicant]
US 6448231B2
· Graham
· 2002
[cited by applicant]
US 6464680B1
· Brisken et al.
· 2002
[cited by applicant]
US 6475160B1
· Sher
· 2002
[cited by applicant]
US 6488673B1
· Laufer et al.
· 2002
[cited by applicant]
US 6506399B2
· Donovan
· 2003
[cited by applicant]
US 6517534B1
· McGovern et al.
· 2003
[cited by applicant]
US 6517535B2
· Edwards
· 2003
[cited by applicant]
US 6526976B1
· Baran
· 2003
[cited by applicant]
US 6546932B1
· Nahon et al.
· 2003
[cited by applicant]
US 6562057B2
· Santin
· 2003
[cited by applicant]
US 6601581B1
· Babaev
· 2003
[cited by applicant]
US 6620415B2
· Donovan
· 2003
[cited by applicant]
US 6623742B2
· Voet
· 2003
[cited by applicant]
US 6626855B1
· Weng et al.
· 2003
[cited by applicant]
US 6632440B1
· Quinn et al.
· 2003
[cited by applicant]
US 6634363B1
· Danek et al.
· 2003
[cited by applicant]
US 6645496B2
· Aoki et al.
· 2003
[cited by applicant]
US 6649161B1
· Donovan
· 2003
[cited by applicant]
US 6658279B2
· Swanson et al.
· 2003
[cited by applicant]
US 6669689B2
· Lehmann et al.
· 2003
[cited by applicant]
US 6685648B2
· Flaherty et al.
· 2004
[cited by applicant]
US 6719694B2
· Weng et al.
· 2004
[cited by applicant]
US 6740321B1
· Donovan
· 2004
[cited by applicant]
US 6767544B2
· Brooks et al.
· 2004
[cited by applicant]
US 6770070B1
· Balbierz
· 2004
[cited by applicant]
US 6773711B2
· Voet et al.
· 2004
[cited by applicant]
US 6776991B2
· Naumann
· 2004
[cited by applicant]
US 6827931B1
· Donovan
· 2004
[cited by applicant]
US 6838434B2
· Voet
· 2005
[cited by applicant]
US 6841156B2
· Aoki et al.
· 2005
[cited by applicant]
US 6843998B1
· Steward et al.
· 2005
[cited by applicant]
US 6846312B2
· Edwards et al.
· 2005
[cited by applicant]
US 6847849B2
· Mamo et al.
· 2005
[cited by applicant]
US 6861058B2
· Aoki et al.
· 2005
[cited by applicant]
US 6872397B2
· Aoki et al.
· 2005
[cited by applicant]
US 6917834B2
· Koblish et al.
· 2005
[cited by applicant]
US 6974578B1
· Aoki et al.
· 2005
[cited by applicant]
US 7027869B2
· Danek et al.
· 2006
[cited by applicant]
US 7184811B2
· Phan et al.
· 2007
[cited by applicant]
US 7371231B2
· Rioux et al.
· 2008
[cited by applicant]
US 7462179B2
· Edwards et al.
· 2008
[cited by applicant]
US 7608275B2
· Deem et al.
· 2009
[cited by applicant]
US 7628789B2
· Soltesz et al.
· 2009
[cited by applicant]
US 7655243B2
· Deem et al.
· 2010
[cited by applicant]
US 7747324B2
· Errico et al.
· 2010
[cited by applicant]
US 7853331B2
· Kaplan et al.
· 2010
[cited by applicant]
US 8007495B2
· McDaniel et al.
· 2011
[cited by applicant]
US 8088127B2
· Mayse et al.
· 2012
[cited by applicant]
US 8105817B2
· Deem et al.
· 2012
[cited by applicant]
US 8133497B2
· Deem et al.
· 2012
[cited by applicant]
US 8172827B2
· Deem et al.
· 2012
[cited by applicant]
US 8226638B2
· Mayse et al.
· 2012
[cited by applicant]
US 8338164B2
· Deem et al.
· 2012
[cited by applicant]
US 8483831B1
· Hlavka et al.
· 2013
[cited by applicant]
US 8489192B1
· Hlavka et al.
· 2013
[cited by applicant]
US 8636684B2
· Deem et al.
· 2014
[cited by applicant]
US 8731672B2
· Hlavka et al.
· 2014
[cited by applicant]
US 8740895B2
· Mayse et al.
· 2014
[cited by applicant]
US 8777943B2
· Mayse et al.
· 2014
[cited by applicant]
US 8808280B2
· Mayse et al.
· 2014
[cited by applicant]
US 8821489B2
· Mayse et al.
· 2014
[cited by applicant]
US 8911439B2
· Mayse et al.
· 2014
[cited by applicant]
US 8932289B2
· Mayse et al.
· 2015
[cited by applicant]
US 8939970B2
· Stone et al.
· 2015
[cited by applicant]
US 8961391B2
· Deem et al.
· 2015
[cited by applicant]
US 8961507B2
· Mayse et al.
· 2015
[cited by applicant]
US 8961508B2
· Mayse et al.
· 2015
[cited by applicant]
US 8979841B2
· Kunis et al.
· 2015
[cited by applicant]
US 9005195B2
· Mayse et al.
· 2015
[cited by applicant]
US 9017324B2
· Mayse et al.
· 2015
[cited by applicant]
US 9125643B2
· Hlavka et al.
· 2015
[cited by applicant]
US 9149328B2
· Dimmer et al.
· 2015
[cited by applicant]
US 9339618B2
· Deem et al.
· 2016
[cited by applicant]
US 9498283B2
· Deem et al.
· 2016
[cited by applicant]
US 9511210B2
· Deem et al.
· 2016
[cited by applicant]
US 9700707B2
· Deem et al.
· 2017
[cited by applicant]
US 20010044596A1
· Jaafar
· 2001
[cited by applicant]
US 20020010460A1
· Joye et al.
· 2002
[cited by applicant]
US 20020013581A1
· Edwards et al.
· 2002
[cited by applicant]
US 20030036755A1
· Ginn
· 2003
[cited by applicant]
US 20030050591A1
· Patrick McHale
· 2003
[cited by applicant]
US 20030113349A1
· Coleman, III
· 2003
[cited by applicant]
US 20030153881A1
· Roche et al.
· 2003
[cited by applicant]
US 20040009180A1
· Donovan
· 2004
[cited by applicant]
US 20040028676A1
· Klein et al.
· 2004
[cited by applicant]
US 20040091880A1
· Wiebusch et al.
· 2004
[cited by applicant]
US 20040226556A1
· Deem et al.
· 2004
[cited by applicant]
US 20040230188A1
· Cioanta et al.
· 2004
[cited by applicant]
US 20040253274A1
· Voet
· 2004
[cited by applicant]
US 20050007441A1
· Hyuga
· 2005
[cited by applicant]
US 20050152924A1
· Voet
· 2005
[cited by applicant]
US 20050171574A1
· Rubinsky et al.
· 2005
[cited by applicant]
US 20050182393A1
· Abboud et al.
· 2005
[cited by applicant]
US 20050281751A1
· Levin
· 2005
[cited by applicant]
US 20060004323A1
· Chang et al.
· 2006
[cited by applicant]
US 20060064086A1
· Odom
· 2006
[cited by applicant]
US 20060153876A1
· Sanders
· 2006
[cited by applicant]
US 20060225742A1
· Deem et al.
· 2006
[cited by applicant]
US 20070021803A1
· Deem et al.
· 2007
[cited by applicant]
US 20070118184A1
· Danek et al.
· 2007
[cited by applicant]
US 20070219600A1
· Gertner et al.
· 2007
[cited by applicant]
US 20070287994A1
· Patel
· 2007
[cited by applicant]
US 20080161890A1
· Lafontaine
· 2008
[cited by applicant]
US 20080312725A1
· Penner
· 2008
[cited by applicant]
US 20090043301A1
· Jarrard et al.
· 2009
[cited by applicant]
US 20090177192A1
· Rioux et al.
· 2009
[cited by applicant]
US 20110257647A1
· Mayse et al.
· 2011
[cited by applicant]
US 20110301587A1
· Deem et al.
· 2011
[cited by applicant]
US 20120302909A1
· Mayse et al.
· 2012
[cited by applicant]
US 20120316552A1
· Mayse et al.
· 2012
[cited by applicant]
US 20130310822A1
· Mayse et al.
· 2013
[cited by applicant]
CA 2152002A1
· 1995
[cited by applicant]
CN 2225227Y
· 1996
[cited by applicant]
EP 3248612A1
· 2017
[cited by applicant]
JP 2002145784A
· 2002
[cited by applicant]
WO 9119529A1
· 1991
[cited by applicant]
WO 9519805A1
· 1995
[cited by applicant]
WO 1999030655A1
· 1999
[cited by applicant]
WO 9934831A1
· 1999
[cited by applicant]
WO 0062699A2
· 2000
[cited by applicant]
WO 2004006954A2
· 2004
[cited by applicant]
WO 2004048519A2
· 2004
[cited by applicant]
WO 2004077987A1
· 2004
[cited by applicant]
WO 2004101028A2
· 2004
[cited by applicant]
WO 2005032646A2
· 2005
[cited by applicant]
WO WO2005030025A2
· 2005
[cited by examiner]
WO 2005048988A1
· 2005
[cited by applicant]
WO 2004101028A3
· 2006
[cited by applicant]
WO 2007014003A2
· 2007
[cited by applicant]
WO 2010077980A1
· 2010
[cited by applicant]
WO 2016183337A2
· 2016
[cited by applicant]
Ahnert-Hilger., et al., “Introduction of Macromolecules into Bovine Adrenal-Medullary Chromaffin Cells and Rat Pheochromocytoma Cells (PC12) by Permeabilization with Streptolysin 0: Inhibitory Effect of Teanus Toxin on …
[cited by applicant]
“Anonymous: Neurotoxin (from Wikipedia),” Retrieved from http://en.wikipedia.org/w/index.php?title=Neurotoxin&printable=yes, Apr. 2, 2015, 23 pages.
[cited by applicant]
Application and File History for U.S. Appl. No. 16/659,893, filed Oct. 22, 2019, Inventors: Deem et al.
[cited by applicant]
Application and File History for U.S. Appl. No. 16/842,209, filed Apr. 7, 2020, Inventors: Deem et al.
[cited by applicant]
Bigalke., et al., “Clostridial Neurotoxins,” Handbook of Experimental Pharmacology (Aktories, K., and Just, I., eds), 2000, vol. 145, pp. 407-443.
[cited by applicant]
Bittner., et al., “Isolated Light Chains of Botulin um Neurotoxins Inhibit Exocytosis,” The Journal of Biological Chemistry, 1989, vol. 264(18), pp. 10354-10360.
[cited by applicant]
Blindt., et al., “Development of a New Biodegradable Intravascular Polymer Stent with Simultaneous Incorporation of Bioactive Substances,” The International Journal of Artificial Organs, 1999, vol. 22 (12), pp. 843-853.
[cited by applicant]
Buzzi., “Diphtheria Toxin Treatment of Human Advanced Cancer,” Cancer Research, 1982, vol. 42, pp. 2054-2058.
[cited by applicant]
Chaddock., et al., “Expression and Purification of Catalytically Active, Non-Toxic Endopeptidase Derivatives of Clostridium Botulinum Toxin Type A,” Protein Expression and Purification, Jul. 2002, vol. 25 (2), pp. 219-2…
[cited by applicant]
Chang., “Cell Poration and Cell Fusion Using an Oscillating Electric Field,” Biophys. J, 1989, vol. 56 (4), pp. 641-652.
[cited by applicant]
De Paiva., et al., “Light Chain of Botulinum Neurotoxin is Active in Mammalian Motor Nerve Terminals When Delivered Via Liposomes,” FEBS Lett, Dec. 1990, vol. 17:277(1-2), pp. 171-174.
[cited by applicant]
Guzman., et al., “Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius,” Ultrasound in medicine & biology, 2003,…
[cited by applicant]
Guzman H.R, et al., “Equilibrium Loading of Cells with Macromolecules by Ultrasound: Effects of Molecular Size and Acoustic Energy,” J Pharm Sci., Jul. 2002, vol. 91 (7), pp. 1693-1701.
[cited by applicant]
Kistner., et al., “Reductive Cleavage of Tetanus Toxin and Botulinum Neurotoxin A by the Thioredoxin System from Brain,” Naunyn-Schmiedebergs Arch Pharmacal, Feb. 1992, vol. 345 (2), pp. 227-234.
[cited by applicant]
Korpela., et al., “Comparison of Tissue Reactions in the Tracheal Mucosa Surrounding a Bioabsorbable and Silicone Airway Stents,” Annals of Thoracic Surgery, 1998, vol. 66, pp. 1772-1776.
[cited by applicant]
Kreitman., “Taming Ricin Toxin,” Nature Biotechnology, 2003, vol. 21, pp. 372-374.
[cited by applicant]
Raj., “Editorial,” Pain Practice, 2004, vol. 4 (1S), pp. S1-S3.
[cited by applicant]
Schmitt G.S., et al., “Indwelling Transbronchial Catheter Drainage of Pulmonary Abscess,” Ann Thorac Surg, Jan. 1988, vol. 45 (1), pp. 43-47.
[cited by applicant]
Shaari., et al., “Rhinorrhea is Decreased in Dogs After Nasal Application of Botulinum Toxin,” Otolaryngol Head Neck Surgery, Apr. 1995, vol. 112 (4), pp. 566-571.
[cited by applicant]
Simpson., et al., “Isolation and Characterization of the botulinum Neurotoxins,” Methods Enzymol, 1988, vol. 165, pp. 76-85.
[cited by applicant]
Simpson L.L., “The Origin, Structure, and Pharmacological Activity of Botulinum Toxin,” Pharmacol Reviews, Sep. 1981, vol. 33 (3), pp. 155-188.
[cited by applicant]
Sundaram, et al., “An Experimental and Theoretical Analysis of Ultrasound-Induced Permeabilization of Cell Membranes,” Biophysical Journal, May 2003, vol. 84 (5), pp. 3087-3101.
[cited by applicant]
Tsuji., et al., “Biodegradable Stents as a Platform to Drug Loading,” International Journal of Cardiovascular Interventions, 2003, vol. 5(1), pp. 13-16.
[cited by applicant]
Unal., et al., “Effect of Botulin um Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial,” Acta Oto-Laryngologica, Dec. 2003, vol. 123 (9), pp. 1060-1063.
[cited by applicant]
Weaver, “Electroporation: A General Phenomenon for Manipulating Cells and Tissues,” Journal of Cellular Biochemistry, Apr. 1993, vol. 51 (4), pp. 426-435.
[cited by applicant]
Fang Chao-xin and Zhen Shao-Shao, Nasal endoscopy combined with multiple radiofrequency for perennial allergic rhinitis, 25(07) J. First Mil. Medic Univ. 876 (Jul. 20, 2005).
[cited by applicant]
Complaint for
[cited by applicant]
Petition for Inter Partes Review of Claims 1-2, 5, 8-10, 12, and 14 of U.S. Pat. No. 10,894,011 Under 35 U.S.C. §312 and 37 C.F.R. §42.104; Case No. IPR2024-00280; served Jan. 18, 2024.
[cited by applicant]
Petition for Inter Partes Review of Claims 1-8 and 11 of U.S. Pat. No. 11,679,077 under 35 U.S.C. §312 and 37 C.F.R. §42.104, Case No. IPR2024-00281; served Jan. 18, 2024.
[cited by applicant]
Petition for Inter Partes Review of Claims 1-3, 7, 9-10, and 17-25 of U.S. Pat. No. 10,610,675 under 35 U.S.C. §312 and 37 C.F.R. §42.104; served Jan. 18, 2024.
[cited by applicant]
IPR2024-00279, Petition for IPR, filed Jan. 18, 2024.
[cited by applicant]
IPR2024-00279, Patent Owner's Preliminary Response, filed Apr. 25, 2024.
[cited by applicant]
IPR2024-00279, Decision Granting IPR, issued Jul. 22, 2024.
[cited by applicant]
IPR2024-00279, Patent Owner's Response, filed Oct. 25, 2024.
[cited by applicant]
IPR2024-00279, Petitioner's Reply to Patent Owner's Response, filed Jan. 17, 2025.
[cited by applicant]
IPR2024-00279, Patent Owner's Sur-Reply, filed Mar. 4, 2025.
[cited by applicant]
IPR2024-00280, Petition for IPR, filed Jan. 18, 2024.
[cited by applicant]
IPR2024-00280, Patent Owner's Preliminary Response, filed Apr. 25, 2024.
[cited by applicant]
IPR2024-00280, Decision Granting IPR, issued Jul. 22, 2024.
[cited by applicant]
IPR2024-00280, Patent Owner's Response, filed Oct. 25, 2024.
[cited by applicant]
IPR2024-00280, Petitioner's Reply to Patent Owner's Response, filed Jan. 17, 2025.
[cited by applicant]
IPR2024-00280, Patent Owner's Sur-Reply, filed Mar. 4, 2025.
[cited by applicant]
IPR2024-00669, Petition for IPR, filed Jan. 18, 2024.
[cited by applicant]
IPR2024-00669, Patent Owner's Preliminary Response, filed Apr. 25, 2024.
[cited by applicant]
IPR2024-00669, Decision Granting IPR, issued Jul. 22, 2024.
[cited by applicant]
IPR2024-00669, Patent Owner's Response, filed Oct. 25, 2024.
[cited by applicant]
IPR2024-00669, Petitioner's Reply to Patent Owner's Response, filed Jan. 17, 2025.
[cited by applicant]
IPR2024-00669, Patent Owner's Sur-Reply, filed Mar. 4, 2025.
[cited by applicant]
Arora et al., “Cryodestruction of Vidian Nerve Branches,” India J. Otolaryngology, vol. 32, No. 3, Sep. 1980, pp. 80-82.
[cited by applicant]
Back et al., “Submucosal Bipolar Radiofrequency Thermal Ablation of Inferior Turbinates: A Long-Tenn Follow-up with Subjective and Objective Assessment,” LarynGoscope, vol. 112, No. 10, Oct. 2002, pp. 1806-1812.
[cited by applicant]
Banhiran, “Quality of life in patients with chronic rhinitis after radiofrequency inferior turbinate reduction,” J. Med Assoc Thai, vol. 93, No. 8, 2010, pp. 950-957.
[cited by applicant]
Bronzino, Medical Devices and Systems, The Biomedical Engineering Handbook (3rd ed. 2006), Chapter 63, Electrosurgical Devices, pp. 63-1-63-9.
[cited by applicant]
Chen et al., “Preliminary study on radiofrequency thermocoagulation of the posterior inferior nerve, anterior ethmoidal nerve, and inferior turbinate under nasal endoscopy for the treatment of perennial allergic rhiniti…
[cited by applicant]
Chen et al., “Radiofrequency Treatment of Nasal Posterior-Under Nerve, Ethmoidal Nerve and Infraturbinal for Perennial Allergic Rhinitis Under Nasal Endoscope,” China Journal of Endoscopy, vol. 11, No. 3, Mar. 2005, pp.…
[cited by applicant]
Coste et al., “Radiofrequency Is a Safe and Effective Treatment of Turbinate Hypertrophy,” LarynGoscope, vol. 111, No. 5, May 2001, pp. 894-899.
[cited by applicant]
Fang et al., “Nasal Endoscopy Combined with Multiple Radiofrequency for Perennial Allergic Rhinitis,” J. First Mil Med Univ, vol. 25, No. 7, 2005, pp. 876-877 (English Translation); IPR2024-00669, “Translator Declaratio…
[cited by applicant]
Haemmerich, “Biophysics of Radiofrequency Ablation,” Critical Reviews in Biomedical Engineering, vol. 38, No. 1, 2010, pp. 53-63.
[cited by applicant]
Haikou, “Diagnostic Criteria and Efficacy Evaluation Criteria of Allergic Rhinitis,” vol. 33, No. 3 Chin. J. Otorhinolaryngol, Jun. 1998, pp. 134-135; IPR2024-00669, “Translation Declaration for Haikou,” Petitioner Exhi…
[cited by applicant]
Hong et al., “Radiofrequency Ablation: Mechanism of Action and Devices,” J. Vasc. Interv. Radiol. Vol. 21, No. 8S, 2010, pp. S179-S186.
[cited by applicant]
Hytonen et al., “Radiofrequency Thermal Ablation for Patients with Nasal Symptoms: A Systematic Review of Effectiveness and Complications,” Eur. Arch. Otorhinolaryngol, vol. 266, 2009, pp. 1257-1266.
[cited by applicant]
Ilgner et al., “Feasibility of coblation versus laser resection in recurrent nasal polyps,” Proc. of SPIE, vol. 5686, Apr. 25, 2005, pp. 322-327.
[cited by applicant]
Kong et al., “Low-temperature plasma ablation of inferior turbinate for the treatment of perennial allergic rhinitis,” J Clin. Otorhinolaryngol, vol. 19, No. 5, Mar. 2005, pp. 214-215 (English Translation); IPR2024-0066…
[cited by applicant]
Kong et al., “Clinical Observation on Radiofrequency Ablation Treatment in Perennial Allergic Rhinitis,” J. Clin Otorhinolaryngol, vol. 19, No. 5, Mar. 2005, pp. 214-215 (English translation); IPR2024-00669, “Translator…
[cited by applicant]
Konno, “Historical, Pathophysiological, and Therapeutic Aspects of Vidian Neurectomy,” Curr. Allergy Asthma Rep., vol. 10, 2010, pp. 105-112.
[cited by applicant]
Koyyalagunta et al., “Radiofrequency and Cryoablation for Cancer Pain,” Techniques in Regional Anesthesia & Pain Management, vol. 14, No. 1, Jan. 2010, pp. 3-9.
[cited by applicant]
Lee et al., “Surgical Management of Turbinate Hypertrophy in the Office: Three Mucosal Sparing Techniques,” Operative Techniques in Ottolaryngology-Head and Neck Surgery, vol. 12, No. 2, Jun. 2001, pp. 107-111.
[cited by applicant]
Levine, “Lasers in Endonasal Surgery,” Otolaryngolog. Clinics of N. Am., vol. 30, No. 3, Jun. 1, 1997, pp. 451-455.
[cited by applicant]
Liang et al., “Radiofrequency Treatment of Ethmoidal Nerve with Allergic Rhinitis Under Nasal Endoscopy,” J. Clint Otorhinolaryngol., vol. 13, No. 8, Aug. 1999, pp. 341-342. (English Translation); IPR2024-00669, “Transl…
[cited by applicant]
Philippson, “Principles of Electrical Resistance of Living Tissue,” Bull. Cl. Sci. Acad. R. Belg., Ser. 5, vol. 7, No. 7, Jul. 1921, pp. 387-403.
[cited by applicant]
Sackenheim, “Radio Frequency Ablation the Key to Cancer Treatment,” J. Diagnostic Medical Sonography, vol. 19, No. 2, 2003, pp. 88-92.
[cited by applicant]
Windsor et al., “Sphenopalatine Ganglion Blockage: A Review and Proposed Modification of the Transnasal Technique,” Pain Physician, vol. 7, 2004, pp. 283-286.
[cited by applicant]
IPR2024-00669, “Transcript of the Oct. 17, 2024, deposition of Dr. Nicolas Bu-Saba,” Patent Owner Exhibit 2002; IPR2024-00669, “Errata from the Oct. 17, 2024 Deposition of Dr. Nicolas Bu-Saba,” Petitioner Exhibit 1100.
[cited by applicant]
IPR2024-00669, “Declaration of Dr. Howard L. Levine,” Patent Owner Exhibit 2003.
[cited by applicant]
IPR2024-00669, “Declaration of Dr. Marom Bikson,” Patent Owner Exhibit 2005.
[cited by applicant]
IPR2024-00669, “Transcript of the Sep. 24, 2024, Deposition of Dr. Gregory T. Martin,” Patent Owner Exhibit 2009; IPR2024-00669, “Errata from the Sep. 24, 2024 Deposition of Dr. Gregory Martin,” Petitioner Exhibit 1101.
[cited by applicant]
IPR2024-00669, “Transcript of the Sep. 25, 2024, Deposition of Dr. Gregory T. Martin” Patent Owner Exhibit 2010; IPR2024-00669, “Errata from the Sep. 25, 2024 Deposition of Dr. Gregory Martin,” Petitioner Exhibit 1102.
[cited by applicant]
IPR2024-00669, “Transcript of the Feb. 21, 2025, deposition of Dr. Nicolas Bu-Saba,” Patent Owner Exhibit 2011.
[cited by applicant]
IPR2024-00669, “Transcript of the Feb. 20, 2025 deposition of Dr. Gregory T. Martin,” Patent Owner Exhibit 2012.
[cited by applicant]
Aerin Medical Inc. v. Neurent Medical Inc., Case No. 1:23-cv-00756- GBW, “Amended Complaint for Patent Infringement,” Dkt. 17 filed Oct. 16, 2023.
[cited by applicant]
IPR2024-00669, “Apr. 1, 2024 Declaration of Dr. Nicolas Bu-Saba,” Petitioner Exhibit 1083.
[cited by applicant]
IPR2024-00669, “Apr. 2, 2024 Declaration of Dr. Gregory Martin,” Petitioner Exhibit 1084.
[cited by applicant]
IPR2024-00669, “Reply Declaration of Dr. Nicolas Bu-Saba,” Jan. 17, 2025, Petitioner Exhibit 1098.
[cited by applicant]
IPR2024-00669, “Declaration of Dr. Gregory Martin Regarding Claim 4 of U.S. Pat. No. 11,697,077,” Jan. 16, 2025, Petitioner Exhibit 1099.
[cited by applicant]
IPR2024-00669, “Excerpts from the Declaration of Dr. Howard L. Levine filed in IPR2017-00498,” Jan. 29, 2018, Petitioner Exhibit 1104.
[cited by applicant]
IPR2024-00669, “Excerpts from the Declaration of Dr. Marom Bikson filed in IPR2022-00511,” Feb. 15, 2022, Petitioner Exhibit 1116.
[cited by applicant]
U.S. Appl. No. 11,450,090, filed Jul. 21, 2006, U.S. Pat. No. 7,608,275, Oct. 27, 2009.
[cited by applicant]
U.S. Appl. No. 12/559,278, filed Sep. 14, 2009, U.S. Pat. No. 8,133,497, Mar. 13, 2012.
[cited by applicant]
U.S. Appl. No. 13/253,595, filed Oct. 5, 2011, U.S. Pat. No. 8,338,164, Dec. 25, 2012.
[cited by applicant]
U.S. Appl. No. 13/660,629, filed Oct. 25, 2012, U.S. Pat. No. 8,961,391, Feb. 24, 2015.
[cited by applicant]
U.S. Appl. No. 14/601,529, filed Jan. 21, 2015, U.S. Pat. No. 9,498,283, Nov. 22, 2016.
[cited by applicant]
U.S. Appl. No. 15/358,187, filed Nov. 22, 2016, U.S. Pat. No. 10,022,529, Jul. 17, 2018.
[cited by applicant]
U.S. Appl. No. 16/036,381, filed Jul. 16, 2018, U.S. Pat. No. 10,729,897, Aug. 4, 2020.
[cited by applicant]
U.S. Appl. No. 16/659,893, filed Oct. 22, 2019, U.S. Pat. No. 10,610,675, Apr. 7, 2020.
[cited by applicant]
U.S. Appl. No. 16/842,209, filed Apr. 7, 2020, U.S. Pat. No. 10,894,011, Jan. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/151,938, filed Jan. 19, 2021, U.S. Pat. No. 11,679,077, Jun. 20, 2023.
[cited by applicant]
U.S. Pat. No. 9,072,597, Aerin Medical Inc. IPR2024-00275.
[cited by applicant]
U.S. Pat. No. 9,415,194, Aerin Medical Inc. IPR2024-00276.
[cited by applicant]
U.S. Pat. No. 11,241,271, Aerin Medical Inc. IPR2024-00277.
[cited by applicant]
U.S. Pat. No. 11,033,318, Aerin Medical Inc. IPR2024-00278.
[cited by applicant]
U.S. Pat. No. 10,610,675, The Foundry LLC, IPR2024-00279.
[cited by applicant]
U.S. Pat. No. 10,894,011, The Foundry LLC, IPR2024-00280.
[cited by applicant]
U.S. Pat. No. 11,679,077, The Foundry LLC, IPR2024-00281 (terminated).
[cited by applicant]
U.S. Pat. No. 11,766,286, Aerin Medical Inc. IPR2024-00282.
[cited by applicant]
U.S. Pat. No. 11,679,077, The Foundry LLC, IPR2024-00669.
[cited by applicant]
Wolf, “How a Serial Entrepreneur Identifies and Evaluates Product Ideas and Brings Them to Market,” Mastering Medical Device, Episode Transcript, 21 pages, https://www.masteringmedicaldevice.com/episodes/wolf, Dec. 12, …
[cited by applicant]
IPR2024-00669, “Declaration of Dr. Nicolas Bu-Saba regarding Claims 1-8 and 11 of U.S. Pat. No. 11,679,077,” Petitioner Exhibit 1002, Jan. 17, 2024.
[cited by applicant]
IPR2024-00669, “Declaration of Dr. Gregory Martin regarding Claim 4 of U.S. Pat. No. 11,679,077,” Petitioner Exhibit 1007, Jan. 15, 2024.
[cited by applicant]
IPR2024-00669, “Deposition Transcript of Dr. Howard Levine” Petitioner Exhibit 1089; IPR2024-00669, “Exhibit 1 to the Deposition of Dr. Howard Levine,” Petitioner Exhibit 1090, Jan. 9, 2025.
[cited by applicant]
IPR2024-00669, “Deposition Transcript of Dr. Marom Bikson” Petitioner Exhibit 1091; “Exhibit A to the Deposition of Dr. Marom Bikson,” Petitioner Exhibit 1092; “Exhibit B to the Deposition of Dr. Marom Bikson,” Petition…
[cited by applicant]
IPR2024-00279, Final Written Decision, entered Jul. 21, 2025.
[cited by applicant]
IPR2024-00280, Final Written Decision, entered Jul. 21, 2025.
[cited by applicant]
IPR2024-00669, Final Written Decision, entered Jul. 21, 2025.
[cited by applicant]